

**The relationship between Nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer(TNBC) patients receiving adjuvant doxorubicin treatment**

Ji-Yeon Kim<sup>1,\*</sup>, Hae Hyun Jung<sup>5,\*</sup>, Soomin Ahn<sup>3</sup>, SooYoun Bae<sup>4</sup>, Se Kyung Lee<sup>4</sup>, Seok Won Kim<sup>4</sup>, Jeong Eon Lee<sup>4</sup>, Seok Jin Nam<sup>4</sup>, Jin Seok Ahn<sup>1</sup>, Young-Hyuck Im<sup>1, 2</sup> and Yeon Hee Park<sup>1, 2, 5</sup>

<sup>1</sup>Division of Hematology-Oncology, Department of Medicine, <sup>2</sup>Biomedical Research Institute,

<sup>3</sup>Cancer of Companion Diagnostics, <sup>4</sup>Department of Surgery, Samsung Medical Center, Seoul 06351,

Korea; <sup>5</sup>Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06351, Korea

## **Supplementary Figure Legends**

**Supplementary Fig. 1.** Patient cohort (N=203)

**Supplementary Fig. 2.** Heatmap for NF-κB pathway associated gene expression

(A) All patients (N=203)

(B) Patients with adjuvant doxorubicin chemotherapy (N=116)

(C) Patients with adjuvant CMF chemotherapy (N=86)


**Supplementary Fig. 3.** Relationship among NF-κB pathway-associated gene expression in TNBC with adjuvant doxorubicin chemotherapy

**Supplementary Table 1.** Relationships among expression of NFKB pathway-associated genes in TNBC


**Supplementary Table 1** Relationships among expression of NFKB pathway-associated genes in TNBC

Clinical variables	NFKB1	NFKB2	RELA	RELB	REL	TP53	FOXC1	TBP	SP1	STAT3	IRF1
<b>NFKB1</b>											
Pearson R	1	-0.074	-0.385	0.084	0.694	0.041	-0.366	0.051	-0.491	-0.286	-0.241
P-value		0.429	<0.001	0.370	<0.001	0.665	<0.001	0.587	<0.001	0.002	0.009
<b>NFKB2</b>											
Pearson R	-0.074	1	0.825	0.728	-0.114	-0.067	0.230	0.541	0.599	0.535	0.391
P-value	0.429		<0.001	<0.001	0.225	0.477	0.013	<0.001	<0.001	<0.001	<0.001
<b>RELA</b>											
Pearson R	-0.385	0.825	1	0.560	-0.441	-0.033	0.449	0.430	0.845	0.697	0.453
P-value	<0.001	<0.001		<0.001	<0.001	0.728	<0.001	<0.001	<0.001	<0.001	<0.001
<b>RELB</b>											
Pearson R	0.084	0.728	0.560	1	0.027	0.203	0.127	0.391	0.349	0.549	0.612
P-value	0.370	<0.001	<0.001		0.777	0.029	0.176	<0.001	<0.001	<0.001	<0.001
<b>REL</b>											
Pearson R	0.694	-0.114	-0.441	0.027	1	0.033	-0.367	0.082	-0.542	-0.313	-0.222
P-value	<0.001	0.225	<0.001	0.777		0.727	<0.001	0.382	<0.001	0.001	0.017
<b>TP53</b>											
Pearson R	0.041	-0.067	-0.033	0.203	0.033	1	-0.009	-0.050	-0.079	-0.012	0.081
P-value	0.665	0.477	0.728	0.029	0.727		0.925	0.595	0.399	0.900	0.385
<b>FOXC1</b>											
Pearson R	-0.366	0.230	0.449	0.127	-0.367	-0.009	1	0.007	0.455	0.273	0.193
P-value	<0.001	0.013	<0.001	0.176	<0.001	0.925		0.942	<0.001	0.003	0.038
<b>TBP</b>											
Pearson R	0.051	0.541	0.430	0.391	0.082	-0.050	0.007	1	0.324	0.249	0.158
P-value	0.587	<0.001	<0.001	<0.001	0.382	0.595	0.942		<0.001	0.007	0.090
<b>SP1</b>											
Pearson R	-0.491	0.599	0.845	0.349	-0.542	-0.079	0.455	0.324	1	0.619	0.398
P-value	<0.001	<0.001	<0.001	<0.001	<0.001	0.399	<0.001	<0.001		<0.001	<0.001
<b>STAT3</b>											
Pearson R	-0.286	0.535	0.697	0.549	-0.313	-0.012	0.273	0.249	0.619	1	0.643
P-value	0.002	<0.001	<0.001	<0.001	<0.001	0.001	0.900	0.003	0.007	<0.001	<0.001
<b>IRF1</b>											
Pearson R	-0.241	0.391	0.453	0.612	-0.222	0.081	0.193	0.158	0.398	0.643	1
P-value	0.009	<0.001	<0.001	<0.001	<0.001	0.017	0.385	0.038	0.090	<0.001	<0.001

**Supplementary Fig. 1.**



**Supplementary Fig. 2.**



Supplementary Fig. 3

